menu search

Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024

Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying eff...

October 13, 2023, 7:50 pm

Apa corporation and totalenergies announce oil project of 200,000 b/d in block 58 and launch development studies with the objective of sanctioning the project by year-end 2024

HOUSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — APA Corporation (Nasdaq: APA) and TotalEnergies have announced the launching of development studies for a...

September 13, 2023, 7:27 pm

Lanzatech global, inc. announces second quarter 2023 financial results

Operating revenues of $12.9 million for second quarter 2023, an increase of 31% over second quarter 2022 Current cash, restricted cash, and investment...

August 9, 2023, 10:01 am

Angle technology to be used in cancer clinical trial

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, announced a significant contract win with Artios Pharma. Under the deal ANG...

May 25, 2023, 2:36 am

Liveramp's $1.1 billion buyback authorization: time to get back in

Yesterday, LiveRamp announced it has increased its share buyback authorization by $100 million to $1.1 billion. That made for a nice headline, but let...

December 22, 2022, 1:23 pm

Ecb's villeroy: determined to get inflation down to around 2% by end 2024 or end 2025

  • Inflation should peak some time in 1H 2023 and then go down
  • ECB will raise rates as much as necessary
  • Voted for a 50 bps rate ...

    December 16, 2022, 7:20 am

Tg therapeutics: ublituximab could achieve $1 billion in annual sales by year-end 2024

TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsi...

December 15, 2022, 2:04 pm


Search within

Pages Search Results: